Bioxytran Investor Relations Material
Latest events
Q1 2025
14 May, 2025
Q3 2024
29 Oct, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Bioxytran Inc
Access all reports
Bioxytran Inc. is a biotechnology company focused on developing therapies for fibrotic and viral diseases. The company specializes in glycovirology, using carbohydrate-based drugs to target viral infections and inflammatory conditions. Its research includes treatments for diseases such as COVID-19 and pulmonary fibrosis, aiming to improve oxygen delivery and tissue regeneration. The company is headquartered in Needham, Massachusetts, and its shares are listed on the OTCQB.
Latest articles
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
)
D. E. Shaw & Co: Inside the Quiet Giant of Quant Finance
A deep dive into D. E. Shaw's evolution from a $28M quant startup to a $65B hedge fund giant, built on research, computing, and quiet consistency.
2 Jul 2025
)
Pershing Square Capital Management: Conviction, Reinvention, and Contrarian Investing
Pershing Square Capital Management has grown into a top-tier hedge fund through reinvention, conviction, and focus on long-term value creation.
2 Jul 2025
Ticker symbol
BIXT
Country
🇺🇸 United States